Related Experiment Video

Updated: May 5, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

9.1K

Small molecule agonists of PPAR-γ exert therapeutic effects in esophageal cancer

Hiroshi Sawayama1, Takatsugu Ishimoto, Masayuki Watanabe

  • 1Authors' Affiliations: Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto; Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka; and Research and Development Division, Daiichi Sankyo Co., Ltd., Tokyo, Japan.

Cancer Research
|November 26, 2013
PubMed

Insights

Efatutazone, a PPAR-γ agonist, inhibits esophageal squamous cell carcinoma (ESCC) proliferation by upregulating p21Cip1. This novel therapeutic shows promise alone or with cetuximab for ESCC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Peroxisome proliferator-activated receptor gamma (PPAR-γ) is involved in lipid metabolism, inflammation, and apoptosis.
  • PPAR-γ agonists, used for diabetes, show potential in cancer therapy.
  • Efatutazone is a novel PPAR-γ agonist with antiproliferative effects in various cancers.

Purpose of the Study:

  • Investigate PPAR-γ status in esophageal squamous cell carcinoma (ESCC).
  • Evaluate the antiproliferative effects of efatutazone in ESCC.
  • Elucidate the molecular mechanisms of efatutazone's action.

Main Methods:

  • Assessed PPAR-γ expression in ESCC tissues.
  • Tested efatutazone's antiproliferative effects in vitro and in vivo.
  • Analyzed efatutazone's impact on signaling pathways like Akt, MAPK, and EGF receptor.

Main Results:

  • PPAR-γ was heterogeneously expressed in ESCC, inversely correlating with Ki-67.
  • PPAR-γ expression was linked to a good prognosis in ESCC.
  • Efatutazone, unlike troglitazone, inhibited ESCC cell proliferation.
  • Efatutazone upregulated nuclear p21Cip1 via Akt pathway inactivation and p21Cip1 dephosphorylation.
  • Efatutazone induced EGF receptor phosphorylation and MAPK pathway activation.
  • Efatutazone combined with cetuximab synergistically inhibited Akt and MAPK pathways.

Conclusions:

  • Efatutazone demonstrates significant antiproliferative activity in ESCC.
  • The mechanism involves p21Cip1 upregulation and modulation of Akt/MAPK pathways.
  • Efatutazone, alone or with cetuximab, holds therapeutic potential for ESCC.

More Related Videos

Subculture and Cryopreservation of Esophageal Adenocarcinoma Organoids: Pros and Cons for Single Cell Digestion10:42

Subculture and Cryopreservation of Esophageal Adenocarcinoma Organoids: Pros and Cons for Single Cell Digestion

Published on: July 6, 2022

3.4K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.6K

Related Concept Videos

Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.9K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.4K
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K